Aleksandra Bzura

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.

Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.

Journal: Nature communications

Published: June 01, 2025

Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.

Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.

Journal: Nature communications

Published: October 11, 2024

Targeting DNA Damage Response Deficiency in Thoracic Cancers.

Targeting DNA Damage Response Deficiency in Thoracic Cancers.

Journal: Drugs

Published: June 07, 2024

Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres.

Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres.

Journal: BMJ open

Published: November 22, 2023

A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma.

A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma.

Journal: Nature communications

Published: October 04, 2023

Family Matters: Germline Testing in Thoracic Cancers.

Family Matters: Germline Testing in Thoracic Cancers.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: May 11, 2023

Accelerating innovations in systemic therapy for pleural mesothelioma.

Accelerating innovations in systemic therapy for pleural mesothelioma.

Journal: Nature cancer

Published: August 23, 2022

BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms.

BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms.

Journal: Oncogene

Published: July 15, 2022

ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance.

ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance.

Journal: Cancer research

Published: February 07, 2022

Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations.

Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: December 15, 2021

Author Correction: Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment.

Author Correction: Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment.

Journal: Nature communications

Published: June 08, 2021

Precision Therapy for Mesothelioma: Feasibility and New Opportunities.

Precision Therapy for Mesothelioma: Feasibility and New Opportunities.

Journal: Cancers

Published: April 07, 2021

Showing 1-12 of 14

Last Updated: 09/26/2026